Guardant Health and ConcertAI have partnered to create a first-of-its-kind multi-modal real-world data (RWD) solution, integrating comprehensive patient EMR data with genomic and epigenomic tumor profiling. By combining Guardant’s liquid biopsy technology with ConcertAI’s AI-driven analytics, the collaboration aims to provide biopharma companies with deeper insights into cancer biology, resistance mechanisms, and tumor evolution across the cancer care continuum. This innovative approach includes unique methylation data from Guardant’s platform and is expected to enhance cancer therapy development, clinical trial design, and precision medicine strategies. Financial terms of the agreement remain undisclosed.
Trending
- Cancer risk comparable across advanced IBD therapies in claims analysis (GI & Hepatology News)
- Independent practice on the road to extinction: Why the next generation won’t own the stethoscope, let alone the building (Medical Economics)
- Fecal Burden on CT Weakly Correlates with Bowel Function in Adults and is Poorly Associated with Clinical Symptoms (Digestive Diseases and Sciences)
- Cook Medical issues medical device correction for Hemospray Endoscopic Hemostat (AGA)
- Medicare physician pay reform 2027: Patients First Act and 4 other bills explained (Physicians Practice)
- FDA Advisory Committee Votes In Favor of Approval of GRAIL’s Galleri® Multi-Cancer Early Detection Test (PR Newswire)
- Batteries that safely break down in the GI tract could improve ingestible devices (Medical Xpress)
- Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls (Gastroenterology)
